| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5307953 | GLAXOSMITHKLINE | Single dose dispenser having a piercing member |
Dec, 2012
(11 years ago) | |
|
US5307953 (Pediatric) | GLAXOSMITHKLINE | Single dose dispenser having a piercing member |
Jun, 2013
(10 years ago) | |
| US5554639 | GLAXOSMITHKLINE | Medicaments |
Sep, 2013
(10 years ago) | |
|
US5554639 (Pediatric) | GLAXOSMITHKLINE | Medicaments |
Mar, 2014
(10 years ago) | |
Imitrex is owned by Glaxosmithkline.
Imitrex contains Sumatriptan.
Imitrex has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Imitrex are:
- US5307953
- US5307953*PED
- US5554639
- US5554639*PED
Imitrex was authorised for market use on 26 August, 1997.
Imitrex is available in spray;nasal dosage forms.
Imitrex can be used as method of treating migraine.
The generics of Imitrex are possible to be released after 10 March, 2014.
Drugs and Companies using SUMATRIPTAN ingredient
Market Authorisation Date: 26 August, 1997
Treatment: Method of treating migraine
Dosage: SPRAY;NASAL
More Information on Dosage
IMITREX family patents
